Page last updated: 2024-11-05

azabutyrone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Azabutyrone is a novel psychoactive compound that has gained attention for its potential as a research tool in the study of the brain. It is synthesized from the precursor molecule, butyrylcholinesterase. Azabutyrone is a potent inhibitor of acetylcholinesterase, an enzyme that breaks down acetylcholine, a neurotransmitter crucial for memory and learning. By inhibiting acetylcholinesterase, azabutyrone increases acetylcholine levels in the brain, potentially leading to enhanced cognitive function. However, the compound's effects on humans are still being investigated, and its safety and long-term consequences are unknown. Research on azabutyrone is ongoing to explore its potential therapeutic applications, particularly in treating Alzheimer's disease and other cognitive impairments. The compound's unique mechanism of action and its ability to modulate acetylcholine levels make it a promising target for future pharmacological research.'

azabutyrone: Russian drug; RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID18483
MeSH IDM0058164
PubMed CID18484
CHEMBL ID1965536
SCHEMBL ID2111662
MeSH IDM0058164

Synonyms (46)

Synonym
azabutyrone
1-butanone, 1-(4-fluorophenyl)-4-(hexahydropyrrolo(1,2-a)pyrazin-2(1h)-yl)-, dihydrochloride
butyrophenone, 4'-fluoro-4-(hexahydropyrrolo(1,2-a)pyrazin-2(1h)-yl)-, dihydrochloride
BIM-0034016.P001
3162-75-2
7wh972m21r ,
azabuperone hydrochloride
unii-7wh972m21r
cambridge id 5806264
1-butanone, 1-(4-fluorophenyl)-4-(hexahydropyrrolo(1,2-a)pyrazin-2(1h)-yl)-, hydrochloride (1:2)
AKOS030506169
4-(3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-2-yl)-1-(4-fluorophenyl)butan-1-one;dihydrochloride
Q27268954
DTXSID60953583
1-(4-fluorophenyl)-4-(hexahydropyrrolo[1,2-a]pyrazin-2(1h)-yl)butan-1-one--hydrogen chloride (1/2)
CBMICRO_033930
CHEMDIV2_000206
NCGC00160491-01
OPREA1_396037
OPREA1_468644
azabuperone
HMS1369J08
4-(3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-2-yl)-1-(4-fluorophenyl)butan-1-one
4'-fluor-4-(perhydropyrrolo(1,2-a)pyrazin-2-yl)butyrophenon
azabuperonum [inn-latin]
unii-9p043590ex
azabuperone [inn]
azabuperona [inn-spanish]
2856-81-7
azabuperonum
4'-fluoro-4-(hexahydropyrrolo(1,2-a)pyrazin-2(1h)-yl)butyrophenone
9p043590ex ,
azabuperona
cas-2856-81-7
dtxsid1046186 ,
tox21_111851
dtxcid9026186
CCG-15718
CHEMBL1965536
AKOS022134126
STL322539
1-(4-fluorophenyl)-4-(hexahydropyrrolo[1,2-a]pyrazin-2(1h)-yl)butan-1-one
4-(1,4-diazabicyclo[4.3.0]non-4-yl)-4'-fluorobutyrophenone
SCHEMBL2111662
4'-fluoro-4-(hexahydropyrrolo[1,2-a]pyrazin-2(1h)-yl)butyrophenone
Q27272843

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"By using gas-chromatographic and spectrophotometric assays and adopting pharmacokinetic models of various types the pharmacokinetics of the neuroleptic azabutyron in the plasms, bile, gastric juice and urine of rabbits and rats was studied."( [Pharmacokinetic study of the neuroleptic, azabutyrone].
Gavlik, I; Ianku, I; Pochatov, IuM; RaevskiÄ­, KS,
)
0.39

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.09070.005612.367736.1254AID624032
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (66.67)24.3611
2020's2 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (20.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]